This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIAD0Z7_L.jpg
The company said it was expecting to take a restructuring charge, which would include expenses related to optimizing its facilities, in the fourth quarter.
The layoffs come on the back of a near $4 billion impairment it took in the third quarter related to its cancer test unit GRAIL.
The company, which is in the process of launching its next-generation NovaSeq X DNA sequencing systems, has over 9,100 employees globally, according to its website.
